Contemporary OB/GYN

10/31/2025

Both 1-mg and 2-mg dienogest regimens significantly reduced pain and dysmenorrhea in patients with , but the lower dose showed better tolerability and smaller hormonal changes, researchers reported.

Read more: https://www.contemporaryobgyn.net/view/low-dose-dienogest-proves-effective-for-endometriosis-pain-relief

10/31/2025

New clinical practice guidelines for managing menopause and perimenopause have been published by the ESE, offering evidence-based recommendations for diagnosis and treatment across age groups.

Read more: https://www.contemporaryobgyn.net/view/new-guidelines-on-menopause-and-perimenopause-management-released

10/31/2025

Caring for moms and moms-to-be — even the spooky ones! 👻 Happy Halloween!

10/30/2025

Infertility is both a physical and emotional challenge, often marked by anxiety, grief, and burnout. Dr. Lucky Sekhon stresses the need for empathy, education, and community support in fertility care.

Full video: https://www.contemporaryobgyn.net/view/addressing-the-emotional-toll-of-infertility

10/30/2025

A new analysis of 2.7M US pregnancies found a rate of 1 in 150 births. Nearly 28% had no identifiable clinical risk factors, underscoring the need for better prediction and prevention tools.

Read more: https://www.contemporaryobgyn.net/view/us-stillbirth-rates-greater-than-previously-reported

10/30/2025

Missed our coverage from The Menopause Society's 2025 Annual Meeting?

No worries, check out the link below for a recap of the top news coming from the conference.



🔗https://hubs.li/Q03R1sXn0

10/29/2025

Following the Dobbs decision, abortion access has been disrupted even in states without restrictions. A study found medication abortion requests doubled post-Dobbs.

Read more: https://www.contemporaryobgyn.net/view/telehealth-abortion-requests-doubled-after-dobbs-decision

10/29/2025

At , researchers reported menopausal status and hormone therapy use may affect outcomes with tirzepatide. Women on hormone therapy or pre/perimenopausal lost nearly 20% body weight vs. 15% in untreated postmenopausal peers.

Read more:

Study finds women on hormone therapy lost more weight with tirzepatide, though researchers stress association—not causation—needs confirmation.

10/29/2025

New research from the Karolinska Institute links postural orthostatic tachycardia syndrome to long COVID, with nearly 30% of long COVID patients meeting diagnostic criteria for .

Read more: https://www.contemporaryobgyn.net/view/mikael-bj-rnson-md-links-long-covid-and-pots

10/28/2025

A study found that immune-mediated fibrosis and vascular changes were linked to symptomatic pelvic floor polypropylene mesh complications, suggesting host response drives adverse outcomes over material breakdown.

Read more: https://www.contemporaryobgyn.net/view/immune-response-may-drive-pelvic-floor-polypropylene-mesh-complications

10/28/2025

At , Dr. Xuezhi Daniel Jiang presented data suggesting menopausal may increase the risk of autoimmune disease in postmenopausal women—contrary to expectations. He emphasized the need for more research.

Full video:

New data suggest hormone therapy may increase autoimmune disease risk in postmenopausal women, highlighting need for clinical vigilance.

10/28/2025

Phase 3 data show zoliflodacin achieved ≥96% cure rates across urogenital, re**al, and pharyngeal infections—including ciprofloxacin-resistant Neisseria . Results support its potential as a single-dose oral therapy.

Read more:

Zoliflodacin study investigator Sarah McLeod, PhD, highlights data presented at IDWeek 2025 in this Q&A.